How Long Does Chickenpox Vaccine Immunity Last?

Chickenpox vaccine protection starts strong but gradually weakens, with the rate of decline depending heavily on whether a person received one dose or two. A single dose can lose more than half its effectiveness within a few years, while two doses maintain protection above 90% for at least the first several years. Beneath the falling antibody levels, though, immune memory cells have been detected up to 20 years after vaccination, which complicates any simple expiration date.

How Quickly Does One Dose Fade?

The original vaccination schedule called for a single shot, and decades of data now show that one dose loses ground steadily. A large national cohort study in South Korea found that one dose was about 86% effective in the first year after vaccination but dropped to roughly 50% over six years, translating to an annual decline of about 7%.¹ A study in the New England Journal of Medicine tracked the rise in breakthrough cases even more starkly: the annual rate of breakthrough chickenpox climbed from about 1.6 per 1,000 person-years in the first year after vaccination to 9.0 at five years and 58.2 at nine years.² Children vaccinated more than five years earlier were also about two and a half times more likely to have moderate or severe disease if they did get a breakthrough case.

A Spanish study confirmed the same pattern from a different angle: a single dose was 93% effective in the first year but fell to around 61% by the third year.³ These findings are why most countries moved to a two-dose schedule. The first dose primes the immune system, but for many children the response simply is not robust enough to hold up over a decade without reinforcement.

What Two Doses Buy You

Adding a second dose dramatically changes the durability picture. A systematic review and meta-analysis that pooled data across studies found the combined effectiveness of two doses at about 95%.⁴ In head-to-head comparisons, the South Korean cohort data showed two doses were about 73% more effective than one at preventing infection.¹

A ten-year follow-up study across five Eastern European countries found that children who received two doses of the combined measles-mumps-rubella-varicella (MMRV) vaccine still had seropositivity rates between 99.5% and 100% at the ten-year mark.⁵ A separate trial following children for about ten years found two-dose MMRV effectiveness of about 95% against any chickenpox and 99% against moderate or severe disease.⁶ By contrast, children in that same trial who only received one varicella dose had effectiveness closer to 67% overall.

Even two doses do wane eventually, though. The meta-analysis estimated that two-dose effectiveness started around 93.5% in the first year and dropped to roughly 50% by nine years, though there was enormous variability between studies in those later time points.⁴ That wide confidence interval at the nine-year mark matters: some populations and vaccine formulations hold up better than others, so treating the late-stage number as a fixed fact would be misleading. What is clear is that two doses buy substantially more years of high-level protection than one dose does.

Antibody Levels Are Only Part of the Story

When researchers talk about immunity “waning,” they usually mean that antibody levels in the blood have dropped below a threshold considered protective. But the immune system has more than one layer of defense. An Italian study of vaccinated healthcare workers estimated that half of them would lose detectable antibodies within about nine years of their last documented positive result.⁷ A Chinese study of children who received two doses found seropositivity rates declining from 100% shortly after vaccination to about 80% over the follow-up period.⁸

Those numbers sound alarming, but losing measurable antibodies does not necessarily mean losing all protection. The immune system also relies on memory T cells and long-lived plasma cells that sit quietly in bone marrow, ready to mount a rapid response if the virus shows up again. A study that directly examined bone marrow samples from adults vaccinated as children found that virus-specific plasma cells and memory T cells persisted for up to 20 years after vaccination.⁹ These cells cannot necessarily prevent infection altogether, but they can help the body fight off the virus faster, which is likely why breakthrough cases in vaccinated people tend to be milder.

Memory T cells are also periodically boosted by low-level reactivations of latent virus in the body and by re-exposure to varicella circulating in the community.¹⁰ This kind of invisible maintenance means the immune system’s functional protection may outlast what a blood test for antibodies would suggest.

What Breakthrough Chickenpox Looks Like

When vaccinated people do catch chickenpox, the illness is usually much milder than what unvaccinated people experience. Fewer lesions, lower fever, faster recovery. A study comparing vaccinated and unvaccinated children in Turkey confirmed this pattern but also found that about a quarter of breakthrough cases were still moderate or severe.¹¹ That one-in-four figure is a useful reality check: vaccination dramatically shifts the odds in your favor, but it does not guarantee a trivial case if you do get infected.

The risk of a more significant breakthrough case also rises as vaccine-induced immunity fades. The New England Journal of Medicine study mentioned earlier found that children vaccinated more than five years prior who developed breakthrough disease were considerably more likely to have a moderate or severe course than those infected soon after vaccination.² This is part of why timing matters: an adolescent or adult whose childhood vaccination has largely waned may not have the same cushion a recently vaccinated child does.

How Vaccine Immunity Compares to Natural Infection

A common question is whether catching chickenpox “the natural way” gives you stronger lifelong immunity than the vaccine does. The answer is nuanced. A study comparing women who were vaccinated to women who had childhood chickenpox found no significant difference in antibody levels years later. But the women who had natural infection had significantly higher levels of virus-specific T cells.¹² In plain terms, both groups were producing similar amounts of antibody, but the naturally infected group had a stronger cellular backup force.

This difference probably explains why natural chickenpox historically conferred what appeared to be lifelong immunity in most people, while vaccine immunity shows more obvious waning. Wild-type infection is a more aggressive and prolonged encounter with the virus, which gives the immune system more material to work with when building its memory. The tradeoff, of course, is that natural chickenpox carries real risks: pneumonia, encephalitis, bacterial skin infections, and occasionally death, particularly in adults. Vaccine immunity may fade faster, but the vaccine avoids those upfront dangers.

One area where the vaccine appears to come out ahead is shingles risk. An older but landmark study of children with leukemia found that those who had natural chickenpox were significantly more likely to later develop shingles than those who had been vaccinated. Among 73 children with a history of chickenpox, 15 went on to develop shingles, compared with none of the 34 vaccinated children during the observation period.¹³ This was a specialized population, so extrapolating to all children requires caution, but the pattern makes biological sense: the vaccine strain appears less likely to establish the kind of deep latent infection in nerve cells that later reactivates as shingles.

Can the Vaccine Strain Itself Cause Shingles?

Yes, though it appears to be rare. The vaccine uses a weakened live virus (the Oka strain), which can establish latency in sensory nerve ganglia just as wild-type varicella does. Reactivation of the vaccine strain has been documented. One case report described a 68-year-old with a healthy immune system who developed herpes zoster caused by the vaccine strain after receiving the shingles vaccine (which uses a higher dose of the same Oka strain). The case was relatively mild and resolved without complications.¹⁴ The broader evidence suggests vaccine-strain shingles occurs at a lower rate than wild-type shingles, which tracks with the leukemia study findings above.

The Community Exposure Factor

There is a fascinating feedback loop between vaccine programs and individual immunity. When chickenpox circulated freely, adults who had already had the disease would periodically encounter infected children, and each exposure gave their immune system a quiet boost. This is known as the exogenous boosting hypothesis, and it has real policy implications. Mathematical models predicted that widespread childhood vaccination would reduce these natural boosting opportunities for older adults, potentially leading to a temporary rise in shingles cases.¹⁵ Some countries actually delayed introducing universal chickenpox vaccination partly because of this concern.

The evidence that exogenous boosting is real, though variable, has since strengthened. A large UK study using electronic health records found that adults who had household exposure to a child with chickenpox were about 33% less likely to develop shingles in the following two years, and that protective effect persisted for up to 20 years after the exposure, albeit at a reduced level.¹⁶ The implication for vaccinated individuals is subtle: as chickenpox becomes rarer due to vaccination programs, people whose vaccine-induced immunity is already waning may get fewer of these incidental boosts. Whether this meaningfully accelerates waning is still being studied.

For vaccinated people specifically, this question is somewhat different from the shingles-in-older-adults scenario, since the vaccine strain establishes a lighter latent infection. But anyone with waning vaccine immunity in a community where chickenpox is rare loses both the antibody response to the vaccine and the periodic natural refreshes that used to come from exposure.

Babies of Vaccinated Mothers

A practical consequence of vaccine-derived immunity that gets less attention is what it means for newborns. Mothers pass antibodies to their babies during pregnancy, providing temporary protection in the first months of life. But how much protection depends on how high the mother’s antibody levels are.

A study that measured varicella antibodies in nearly 200 infant blood samples found that about a third of babies were susceptible to chickenpox by one month of age, rising to nearly 80% by three months. By six months, essentially all infants in the study were susceptible, with antibody levels well below the protective threshold.¹⁷ This study included mothers in a post-vaccination era, where a growing proportion of women of childbearing age were vaccinated rather than naturally infected. Since vaccine-derived antibody levels tend to be lower than those from natural infection, the concern is that babies born to vaccinated mothers may have a shorter window of passive protection than babies born a generation earlier.

This gap matters because children cannot receive the varicella vaccine until 12 months of age in most countries. The months between loss of maternal antibodies and eligibility for vaccination represent a vulnerability window that may be wider for babies of vaccinated mothers than for babies of mothers who had chickenpox as children.

Adults Who Were Vaccinated as Healthcare Workers

Healthcare workers are a population where waning immunity has direct occupational consequences, since they regularly encounter patients with varicella or shingles. A study of 101 healthcare workers with documented two-dose vaccination found that about 12% were seronegative when tested afterward, and roughly another 12% of those who were seropositive produced low-quality antibodies suggesting a suboptimal immune response.¹⁸ The Italian healthcare worker study noted a sex difference in antibody persistence: men lost detectable antibodies faster than women, with a rate of seronegativity roughly 1.75 times higher.⁷

For healthcare settings, these findings raise the question of whether periodic antibody testing or booster doses should be considered, particularly for workers vaccinated many years ago who handle high-risk patients. Current practice in most institutions is to accept documentation of two doses as evidence of immunity, but these studies suggest that a meaningful minority of two-dose recipients may not be well protected based on antibody levels alone.

People With Weakened Immune Systems

Immunity duration is even harder to predict in people whose immune systems are compromised. The vaccine uses a live, weakened virus, which means it cannot be given to people with severely suppressed immune systems. However, vaccination before immune compromise begins, such as before cancer treatment or organ transplant, often produces a response that remains at least partially protective even during treatment.¹⁹ And once the level of immune suppression is reduced, re-vaccination can be safely attempted.

The practical advice for people facing immune-suppressing treatment is straightforward: if you have not already been vaccinated or had chickenpox, get vaccinated before treatment starts if at all possible. The immune response may not be as strong or as durable as in a healthy person, but partial protection is vastly better than none when your defenses are down.

Why Testing Your Immunity Is Trickier Than You’d Think

You might assume that a simple blood test could tell you whether you are still protected. In practice, serological testing for varicella immunity is surprisingly unreliable. The standard commercial antibody tests (ELISAs) correlate reasonably well with each other, but they correlate poorly with the more sensitive fluorescent-antibody-to-membrane-antigen (FAMA) test, which is considered the reference standard.²⁰ This means that a person who tests “negative” on a standard commercial assay might actually still have functional immunity, and vice versa.

This limitation is particularly relevant for vaccinated individuals, whose antibody levels tend to be lower than those produced by natural infection. The commercial tests were largely calibrated against naturally immune populations, where antibody concentrations are higher and easier to detect. A vaccinated person hovering near the threshold can flip between “positive” and “negative” depending on which kit the lab uses. This is why many public health agencies accept documentation of two vaccine doses as proof of immunity rather than relying on post-vaccination antibody testing, and why a negative result on a commercial test in someone known to be vaccinated should be interpreted cautiously.

What Happens at the Population Level When Chickenpox Disappears

One concern that health authorities have grappled with is the age-shift effect. When nearly all young children are vaccinated, the few who slip through or whose immunity wanes may encounter the virus later in adolescence or adulthood, when chickenpox tends to be more dangerous. Mathematical modeling of this scenario suggests the concern is real but limited: the adult cases that emerge after vaccine-induced immunity wanes tend to be mild breakthrough infections rather than full-blown primary chickenpox.²¹

A Danish modeling study found that after introducing universal vaccination, total varicella incidence dropped across all age groups, including adolescents and adults. There was a small temporary bump in cases among school-age children in the first couple of decades, but even that was far below pre-vaccination levels.²² The overall pattern across countries that have adopted two-dose programs is that the benefits of dramatically reduced disease burden far outweigh the modest risks of age-shifting.

The Role of Aging Immune Systems in Vaccine Durability

A recent study in Science Advances shed light on why the varicella vaccine seems to generate more durable protection when given to young people than when given at older ages. The researchers found that younger vaccinees developed a specific subset of memory T cells, known as TH17 cells, that compensated for declines in other immune cell types that naturally occur with aging. Older adults vaccinated with the same live-attenuated vaccine did not generate this compensating response, which may partly explain why their protection fades faster.²³ This finding has implications beyond chickenpox: it points toward a broader principle that the age at which you receive a live vaccine can affect how long the protection lasts, and that newer adjuvanted vaccines may be able to overcome this gap for older recipients.